Fidelity Parent FMR Holds 5.6% Of Danaher, Certifies It Isn't Seeking Control

FMR and chairman Abigail Johnson report 39,184,954.77 shares of Danaher as of September 30, a passive position.

Share
Fidelity Parent FMR Holds 5.6% Of Danaher, Certifies It Isn't Seeking Control

FMR LLC, the parent of Fidelity, holds 5.6% of Danaher, or 39,184,954.77 shares, as of September 30, according to a passive ownership filing (a Schedule 13G) made Thursday. Danaher, which makes instruments, consumables, software and services for biotechnology, life sciences and diagnostics, was the subject of the report, and FMR certified it did not buy the stake to influence control.

Who holds the 39 million shares

FMR reported sole voting power over 35,309,085.54 of the shares and shared voting power over none. Chairman and CEO Abigail P. Johnson is a joint filer on the same 39,184,954.77 shares, with no voting power of her own.

FMR signed a certification that the shares were bought and are held in the ordinary course of business, not to change or influence control of Danaher. The filing says one or more other persons have the right to receive dividends or sale proceeds from the stock, though no single one has more than 5% of the outstanding shares.

An exhibit lists the Fidelity entities behind the position, including Fidelity Management & Research Company, FIAM, Fidelity Management Trust Company and Strategic Advisers. It says Johnson family members, as predominant owners of Series B voting shares, hold 49% of the voting power of FMR.

A stock under pressure after earnings

Danaher shares traded at $226.88 in Thursday trading, down 3.43% from the prior close, giving the company a market value of $165.2 billion.

The company's third-quarter results, reported October 21, showed higher sales and earnings than a year earlier, according to a Yahoo Finance report. A separate report said several brokerages have since raised price targets, clustering in roughly the $250 to $275 range, while Stifel flagged expected respiratory-testing headwinds heading into the fourth quarter.

Danaher's Cepheid unit also won FDA clearance for a hemorrhagic fever test.

Danaher management is scheduled to appear at UBS and Jefferies healthcare conferences, per Yahoo Finance.

Sources

More on Danaher

All Danaher (DHR) coverage →